Your browser doesn't support javascript.
loading
Broad receptor tropism and immunogenicity of a clade 3 sarbecovirus.
Lee, Jimin; Zepeda, Samantha K; Park, Young-Jun; Taylor, Ashley L; Quispe, Joel; Stewart, Cameron; Leaf, Elizabeth M; Treichel, Catherine; Corti, Davide; King, Neil P; Starr, Tyler N; Veesler, David.
Afiliación
  • Lee J; Department of Biochemistry, University of Washington, Seattle, Washington, USA.
  • Zepeda SK; Department of Biochemistry, University of Washington, Seattle, Washington, USA.
  • Park YJ; Department of Biochemistry, University of Washington, Seattle, Washington, USA.
  • Taylor AL; Howard Hughes Medical Institute, Seattle, WA 98195, USA.
  • Quispe J; Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.
  • Stewart C; Department of Biochemistry, University of Washington, Seattle, Washington, USA.
  • Leaf EM; Department of Biochemistry, University of Washington, Seattle, Washington, USA.
  • Treichel C; Department of Biochemistry, University of Washington, Seattle, Washington, USA.
  • Corti D; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA.
  • King NP; Department of Biochemistry, University of Washington, Seattle, Washington, USA.
  • Starr TN; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA.
  • Veesler D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
bioRxiv ; 2023 Sep 13.
Article en En | MEDLINE | ID: mdl-37745523
ABSTRACT
Although Rhinolophus bats harbor diverse clade 3 sarbecoviruses, the structural determinants of receptor tropism along with the antigenicity of their spike (S) glycoproteins remain uncharacterized. Here, we show that the African Rinolophus bat clade 3 sarbecovirus PRD-0038 S has a broad ACE2 usage and that RBD mutations further expand receptor promiscuity and enable human ACE2 utilization. We determined a cryoEM structure of the PRD-0038 RBD bound to R. alcyone ACE2, explaining receptor tropism and highlighting differences with SARS-CoV-1 and SARS-CoV-2. Characterization of PRD-0038 S using cryoEM and monoclonal antibody reactivity revealed its distinct antigenicity relative to SARS-CoV-2 and identified PRD-0038 cross-neutralizing antibodies for pandemic preparedness. PRD-0038 S vaccination elicited greater titers of antibodies cross-reacting with vaccine-mismatched clade 2 and clade 1a sarbecoviruses compared to SARS-CoV-2 S due to broader antigenic targeting, motivating the inclusion of clade 3 antigens in next-generation vaccines for enhanced resilience to viral evolution.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: BioRxiv Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: BioRxiv Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos